Previous Topic Back Forward Next Topic
Print Page Dr. Frank Dieterle
 
Research TutorialsResearch Tutorials MetabonomicsMetabonomics Applications in Drug DevelopmentApplications in Drug Development Specific BiomarkersSpecific Biomarkers PhospholipidosisPhospholipidosis PAG as Biomarker for PhospholipidosisPAG as Biomarker for Phospholipidosis
Home
News
About Me
Ph. D. Thesis
Publications
Research Tutorials
  Metabonomics
    Biology and "-omics"
    Definition of Metabonomics
    Methods
    Applications in Drug Development
      Possiblities and Examples
      Specific Biomarkers
        Phospholipidosis
          PAG as Biomarker for Phospholipidosis
          Amiodarone Study
          Monitoring Drug Candidates
      Patterns of Biomarkers
      Structure Elucidation of New Biomarkers
    Acknowledgements
Links
Contact
Search
Site Map
Guestbook
Print this Page Print this Page

Phenylacetylgycine as Specific Biomarker for Phospholipidosis

Recently phenylacetylglycine (PAG) has been proposed as specific biomarker for phospholipidosis (J.K. Nicholson et al., A metabonomic approach to the investigation of drug-induced phospolipidosis, Biomarkers, 5(6), 2000: 410-423). Phenylacetylglycine is an endogenous metabolite excreted into urine by most species (as adduct of phenylacetate and glycine in the phenylalanine metabolism). In the case of phospholipidosis the concentration levels of PAG in urine are significantly increased.

Chemical structure of phenylacetylglycine (PAG)

 

 

 

Page 155 © Dr. Frank Dieterle, 14.08.2006 Navigation